Astellas Pharma Inc. (ALPMY) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - General industry. The company is headquartered in Tokyo, Japan. The current CEO is Naoki Okamura.
ALPMY has IPO date of 2009-12-29, 14,754 full-time employees, listed on the Other OTC, a market capitalization of $28.7B.
Astellas Pharma Inc. is a Tokyo-based pharmaceutical company founded in 1923 that engages in the manufacture, marketing, and distribution of prescription drugs across major global markets. The company maintains a diverse portfolio spanning oncology, urology, immunology, and infectious disease, with notable products including XTANDI for prostate cancer, XOSPATA for acute myeloid leukemia, PADCEV for urothelial cancer, and immunosuppressants Prograf and Advagraf used in organ transplantation. Beyond its marketed medicines, Astellas actively pursues innovation through strategic collaborations with leading research institutions including Harvard University and biopharmaceutical companies such as Merck, Cytokinetics, and Actinium Pharmaceuticals, with particular focus on cell therapy, targeted radiotherapy, and epigenetic therapies. The company's pipeline and research initiatives reflect its commitment to addressing significant unmet medical needs in oncology, nephrology, and other therapeutic areas.
